The U.S. Food and Drug Administration granted full approval to brexucabtagene autoleucel (Tecartus), a CAR T-cell therapy for relapsed or refractory mantle cell lymphoma (MCL), marking a major advance in treatment. According to Lore Gruenbaum of Blood Cancer United, the approval also raises new questions about how best to use this powerful therapy.
The decision was supported by results from the ZUMA-2 trial, which showed a 91% overall response rate and complete response rates between 62% and 79%, offering some patients the possibility of long-term remission with a single treatment.
Despite this progress, challenges remain. High-risk patients, such as those with TP53 mutations or aggressive disease forms, often do not respond as well. Doctors must also decide whether to use CAR T therapy earlier or later in treatment.
New therapies are being developed, including bispecific antibodies, next-generation BTK inhibitors, improved BCL2 inhibitors, and off-the-shelf CAR T options, aiming to provide more flexible and personalized treatment strategies for patients.